胸主动脉腔内修复时机对无并发症B型主动脉夹层结局的影响:血管外科学会血管质量倡议夹层上市后项目
基于VQI PAS 606例无并发症B型主动脉夹层患者,按TEVAR时机分为24小时内(8例)、1-14天(121例)、15-90天(77例)三组。三组30天和1年死亡率无统计学差异,3年再干预无差异;多变量分析仅术后治疗性腰大池引流与死亡率相关(HR=7.595)。
要点
- 24小时内TEVAR组仅8例,样本过小无法有效统计比较,可能代表高风险亚组。
- 1-14天组与15-90天组在早期死亡率、术后并发症或1年生存率方面无差异。
- 术后需治疗性腰大池引流是唯一预测死亡的风险因素(HR=7.595)。
核心结论
- 24小时内TEVAR患者不常见(N=8),样本太小无法进行有效统计比较,可能代表高风险亚组,表现为并发症风险更高。
- 尽管急性期(1-14天)有生存改善趋势,但与亚急性期(15-90天)相比,在早期死亡率、术后并发症或1年生存率方面结局无差异。
- 这些数据提示,正确选择患者进行早期TEVAR可获得等效的生存和早期结局。
研究设计与样本
- 基于血管外科学会血管质量倡议上市后研究(VQI PAS)数据,共纳入606例无并发症B型主动脉夹层患者。
- 排除急诊病例(N=206)后,按SVS/STS报告指南根据夹层发病后治疗时机分为24小时内(N=8)、1-14天(N=121)和15-90天(N=77)三组。
- 采用单变量和多变量分析比较时机组间术后死亡率、院内并发症和再干预差异。
主要发现
- 三组人口学和合并症相似;24小时内组基线肌酐升高(>1.8 mg/dL)/慢性终末期肾病和「紧急」指定比例更高,1-14天组术前β受体阻滞剂治疗率更高。
- 术后卒中、充血性心力衰竭和肾缺血在24小时内组更常见,但死亡率未增加。
- 未调整30天死亡率三组分别为0%、3.3%和5.2%(P=.68),1年死亡率分别为0%、8.3%和18.2%(P=.06),各时间点均无统计学差异。
- 3年再干预率三组无差异。
- 多变量分析显示术后需治疗性腰大池引流是唯一预测死亡的风险因素(风险比=7.595,95%置信区间:1.730-33.337,P=.007)。
局限性
- 24小时内TEVAR组仅8例,样本太小无法进行有效统计比较。
- 24小时内组可能代表高风险亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The timing of thoracic endovascular aortic repair (TEVAR) after the onset of uncomplicated acute type B aortic dissection (uTBAD) remains controversial. The objective of this study was to evaluate the Society for Vascular Surgery Vascular Quality Initiative (VQI) postapproval study (VQI PAS) data for the impact of TEVAR timing for uTBAD on early and late outcomes, including mortality, procedural complications, and long-term reintervention. METHODS: The VQI PAS used for this analysis includes a total of 606 patients. Patients with uTBAD (defined as those without rupture or malperfusion) exclusive of cases categorized as emergent (N = 206) were divided into groups defined by the Society for Vascular Surgery/Society of Thoracic Surgeons reporting guidelines based on the timing of treatment after the onset of dissection: within 24 hours (N = 8), 1 to 14 days (N = 121), and 15 to 90 days (N = 77). Univariate and multivariable analysis were used to determine differences between timing groups for postoperative mortality, in-hospital complications, and reintervention. RESULTS: Demographics and comorbid conditions were very similar across the 3 TEVAR timing groups. Notable differences included a higher prevalence of baseline elevated creatinine (>1.8 mg/dL)/chronic end-stage renal disease and designation as "urgent" in the <24-hour group, as well as a higher rate of preoperative β-blocker therapy in the 1- to 14-day group. Postoperative stroke, congestive heart failure, and renal ischemia were more common in the <24-hour group without an increase in mortality. Unadjusted 30-day mortality across groups was lowest in the early TEVAR group (0%, 3.3%, and 5.2%; P = .68), as was 1-year mortality (0%, 8.3%, and 18.2%; P = .06), although not statistically different at any time point. Reintervention out to 3 years was not different between the groups. Multivariable analysis demonstrated the need for a postoperative therapeutic lumbar drain to be the only a predictive risk factor for mortality (hazard ratio = 7.595, 95% confidence interval: 1.730-33.337, P = .007). When further subdivided into patients treated 1 to 7 days or 8 to 14 days after dissection, findings were similar. CONCLUSIONS: Patients with uTBAD treated within 24 hours were unusual (N = 8), too small for valid statistical comparison, and likely represent a high-risk subgroup, which is manifested in a higher risk of complications. Although there was a trend toward improved survival in the acute (1- to 14-day) phase, outcomes did not differ compared with the subacute (15- to 90-day) phase with relation to early mortality, postoperative complications, or 1-year survival. These data suggest that the proper selection of patients for early TEVAR can result in equivalent survival and early outcomes.
引用
- Beck AW, Wang G, Lombardi JV, et al. Impact of thoracic endovascular aortic repair timing on outcomes after uncomplicated type B aortic dissection in the Society for Vascular Surgery Vascular Quality Initiative postapproval project for dissection. J Vasc Surg. 2023. PMID: 36603666. doi:10.1016/j.jvs.2022.12.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。